The Developmental Core (Core B) will be established to support the research needs of the members of NCCFAR located at UC Davis, the Viral and Rickettsial Disease Laboratory of the California Department of Health Services, and UC Berkeley. The main objective of the Developmental Core is to provide financial support to meritorious pilot projects in clinical, epidemiological, social, behavioral, basic science and translational research that encompass all aspects of HIV infection. Funds will be provided to innovative pilot studies through a competitive review process instituted by the Developmental Core. This will allow HIV investigators to generate sufficient preliminary results to compete for extramural funding for their research programs from federal and non-federal granting agencies. Funds will stimulate and foster multi-disciplinary collaborative pilot studies among investigators from Davis and Berkeley sites of NCCFAR and recruit new investigators to HIV research. Funding from the Developmental Core will be important in developing new, as well as multi-disciplinary collaborative HIV research programs, at the NCCFAR. The Developmental Core will also provide funding to junior investigators and graduate students for short-term training. Funds will allow them to visit laboratories of their collaborators or other investigators to receive training in needed methodology, assays or data analysis. In summary, the Developmental Core will be a valuable resource of funding for HIV researchers and new investigators for their innovative research projects, so that they can perform proof-of-concept experiments, obtain preliminary results and seek extramural funding. Thus, the Developmental Core will play a crucial role in facilitating the preparation of a full CFAR application from UC Davis and participating institutions in the future.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI049366-02
Application #
6654020
Study Section
Special Emphasis Panel (ZAI1)
Project Start
2002-09-01
Project End
2003-07-31
Budget Start
Budget End
Support Year
2
Fiscal Year
2002
Total Cost
Indirect Cost
Name
University of California Davis
Department
Type
DUNS #
094878337
City
Davis
State
CA
Country
United States
Zip Code
95618
Sena, Angela A S; Glavan, Tiffany; Jiang, Guochun et al. (2016) Divergent Annexin A1 expression in periphery and gut is associated with systemic immune activation and impaired gut immune response during SIV infection. Sci Rep 6:31157
Dubie, Robert A; Maksaereekul, Saipiroon; Shacklett, Barbara L et al. (2009) Co-immunization with IL-15 enhances cellular immune responses induced by a vif-deleted simian immunodeficiency virus proviral DNA vaccine and confers partial protection against vaginal challenge with SIVmac251. Virology 386:109-21
Asmuth, D M; Abel, K; George, M D et al. (2008) Pegylated interferon-alpha 2a treatment of chronic SIV-infected macaques. J Med Primatol 37:26-30
George, M D; Verhoeven, D; McBride, Z et al. (2006) Gene expression profiling of gut mucosa and mesenteric lymph nodes in simian immunodeficiency virus-infected macaques with divergent disease course. J Med Primatol 35:261-9
Kuekrek, Haydar; Schlingmann, Tobias; Valdez, Hernan et al. (2005) Differential effect of interleukin-2 treatment on primary and secondary immunizations in HIV infected individuals. AIDS 19:1967-74
Israel-Ballard, Kiersten; Chantry, Caroline; Dewey, Kathryn et al. (2005) Viral, nutritional, and bacterial safety of flash-heated and pretoria-pasteurized breast milk to prevent mother-to-child transmission of HIV in resource-poor countries: a pilot study. J Acquir Immune Defic Syndr 40:175-81
Sankaran, Sumathi; Guadalupe, Moraima; Reay, Elizabeth et al. (2005) Gut mucosal T cell responses and gene expression correlate with protection against disease in long-term HIV-1-infected nonprogressors. Proc Natl Acad Sci U S A 102:9860-5
George, Michael D; Reay, Elizabeth; Sankaran, Sumathi et al. (2005) Early antiretroviral therapy for simian immunodeficiency virus infection leads to mucosal CD4+ T-cell restoration and enhanced gene expression regulating mucosal repair and regeneration. J Virol 79:2709-19